Robert M. Wenham

8.4k total citations · 2 hit papers
158 papers, 4.7k citations indexed

About

Robert M. Wenham is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Robert M. Wenham has authored 158 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Reproductive Medicine, 66 papers in Oncology and 40 papers in Obstetrics and Gynecology. Recurrent topics in Robert M. Wenham's work include Ovarian cancer diagnosis and treatment (85 papers), Endometrial and Cervical Cancer Treatments (35 papers) and PARP inhibition in cancer therapy (25 papers). Robert M. Wenham is often cited by papers focused on Ovarian cancer diagnosis and treatment (85 papers), Endometrial and Cervical Cancer Treatments (35 papers) and PARP inhibition in cancer therapy (25 papers). Robert M. Wenham collaborates with scholars based in United States, United Kingdom and Germany. Robert M. Wenham's co-authors include Jin Q. Cheng, Domenico Coppola, Nisha Bansal, Patricia A. Kruk, Jiawang Wang, Santo V. Nicosia, Lili He, William Kong, Hua Yang and Jianjun Zhao and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Robert M. Wenham

149 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MicroRNA Expression Profiling in Human Ovarian Cancer: miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN

2008 881 citations Robert M. Wenham et al. profile →
Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

2007 574 citations Ursula A. Matulonis, Robert M. Wenham et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert M. Wenham United States	33	2.3k	1.4k	1.4k	1.4k	632	158	4.7k
Stéphanie Lheureux Canada	27	1.8k 0.8×	1.7k 1.2×	1.1k 0.8×	1.6k 1.1×	526 0.8×	153	4.3k
Seiji Mabuchi Japan	42	2.4k 1.0×	1.5k 1.0×	1.1k 0.8×	1.6k 1.2×	1.4k 2.2×	192	5.7k
Hiroaki Itamochi Japan	36	1.8k 0.8×	1.3k 0.9×	649 0.5×	1.1k 0.8×	623 1.0×	139	3.6k
Alain G. Zeimet Austria	43	2.2k 0.9×	1.3k 0.9×	991 0.7×	2.1k 1.5×	479 0.8×	173	5.1k
Elena Ioana Braicu Germany	40	2.1k 0.9×	2.3k 1.6×	1.2k 0.9×	1.7k 1.3×	925 1.5×	303	5.4k
Achim Rody Germany	34	1.5k 0.7×	699 0.5×	1.1k 0.8×	1.6k 1.2×	654 1.0×	238	4.6k
Daniel Rosen United States	37	2.6k 1.1×	1.0k 0.7×	1.0k 0.7×	1.5k 1.1×	243 0.4×	87	4.9k
Kenjiro Sawada Japan	40	2.7k 1.2×	789 0.6×	1.5k 1.1×	1.3k 1.0×	478 0.8×	137	5.0k
Steffen Hauptmann Germany	42	2.1k 0.9×	623 0.4×	1.0k 0.8×	1.4k 1.0×	312 0.5×	111	4.9k
Rouba Ali‐Fehmi United States	39	1.2k 0.5×	1.3k 0.9×	874 0.6×	811 0.6×	1.6k 2.5×	152	4.2k

Countries citing papers authored by Robert M. Wenham

Since Specialization

Citations

This map shows the geographic impact of Robert M. Wenham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Wenham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Wenham more than expected).

Fields of papers citing papers by Robert M. Wenham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert M. Wenham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Wenham. The network helps show where Robert M. Wenham may publish in the future.

Co-authorship network of co-authors of Robert M. Wenham

This figure shows the co-authorship network connecting the top 25 collaborators of Robert M. Wenham. A scholar is included among the top collaborators of Robert M. Wenham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert M. Wenham. Robert M. Wenham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chawla, Sant P., et al.. (2024). SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-F_HAB) and atezolizumab in patients with platinum-resistant ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS5629–TPS5629. 2 indexed citations

Harter, Philipp, Pauline Wimberger, Aikou Okamoto, et al.. (2024). Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial. Gynecologic Oncology. 190. S65–S66. 3 indexed citations

Aghajanian, Carol, Barbara Schmalfeldt, Aikou Okamoto, et al.. (2024). 751P Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial. Annals of Oncology. 35. S570–S571. 1 indexed citations

Marth, Christian, Tjoung‐Won Park‐Simon, Carol Aghajanian, et al.. (2023). #1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial. VBN Forskningsportal (Aalborg Universitet). A428.3–A429. 2 indexed citations

Hoogland, Aasha I., Brent J. Small, Laura B. Oswald, et al.. (2023). Relationships among Inflammatory Biomarkers and Self-Reported Treatment-Related Symptoms in Patients Treated with Chemotherapy for Gynecologic Cancer: A Controlled Comparison. Cancers. 15(13). 3407–3407. 5 indexed citations

Tanyi, János L., Leslie M. Randall, Setsuko K. Chambers, et al.. (2023). A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006). Obstetrical & Gynecological Survey. 78(6). 341–342.

Martin, Alexandra, Carmen M. Anadon, Subir Biswas, et al.. (2022). Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors. Molecular Cancer Therapeutics. 21(7). 1184–1194. 23 indexed citations

Fu, Siqing, Bradley R. Corr, Kerry Culm-Merdek, et al.. (2022). Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Journal of Clinical Oncology. 40(23). 2568–2577. 36 indexed citations

Martin, Alexandra, Sweta Sinha, Lauren C. Peres, et al.. (2022). The impact of distance to closest negative margin on survival after pelvic exenteration. Gynecologic Oncology. 165(3). 514–521. 6 indexed citations

10.

Marchion, Douglas C., Susan McCarthy, Ardeshir Hakam, et al.. (2021). Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes. PLoS ONE. 16(11). e0256615–e0256615. 3 indexed citations

11.

Oza, Amit M., Maria Del Pilar Estevez-Diz, Eva‐Maria Grischke, et al.. (2020). A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer. Clinical Cancer Research. 26(18). 4767–4776. 89 indexed citations

12.

Conley, Claire C., Mary K. Townsend, Michelle Kuznicki, et al.. (2019). Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute‐Comprehensive Cancer Center. Clinical Genetics. 97(2). 370–375. 9 indexed citations

13.

Piedmonte, Marion, Paul K. J. Han, Richard P. Moser, et al.. (2017). Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study. Obstetrical & Gynecological Survey. 72(6). 336–337. 1 indexed citations

14.

Fabbro, Michel, Kathleen N. Moore, Anne Dørum, et al.. (2017). Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC). Annals of Oncology. 28. v332–v332. 7 indexed citations

15.

Dossett, Lesly A., Samir Dalia, Damon R. Reed, et al.. (2015). Clinical and pathologic predictors of survival in patients with endometrial stromal sarcoma.. 1(3). 253–261. 1 indexed citations

16.

Rodriguez, Gustavo C., H. John Barnes, Kenneth E. Anderson, et al.. (2013). Evidence of a Chemopreventive Effect of Progestin Unrelated to Ovulation on Reproductive Tract Cancers in the Egg-laying Hen. Cancer Prevention Research. 6(12). 1283–1292. 13 indexed citations

17.

Secord, Angeles Alvarez, Deanna Teoh, William T. Barry, et al.. (2012). A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer. Clinical Cancer Research. 18(19). 5489–5498. 50 indexed citations

18.

Wong, Shirley, Sumitra Ananda, Ignace Vergote, et al.. (2012). A PHASE 1B STUDY OF TREBANANIB (AMG 386) IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) OR TOPOTECAN (T) IN WOMEN WITH RECURRENT OVARIAN CANCER. Asia-Pacific Journal of Clinical Oncology. 8. 316–317. 1 indexed citations

19.

Bansal, Nisha, William S. Roberts, Sachin M. Apte, Johnathan M. Lancaster, & Robert M. Wenham. (2009). Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for pelvic exenterations. Journal of Surgical Oncology. 100(6). 511–514. 7 indexed citations

20.

Hakim, Amy, H. John Barnes, Kenneth E. Anderson, et al.. (2009). Ovarian Adenocarcinomas in the Laying Hen and Women Share Similar Alterations in p53, ras, and HER-2/neu. Cancer Prevention Research. 2(2). 114–121. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact